Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells

Marion Dajon, Kristina Iribarren, Florent Petitprez, Solenne Marmier, Audrey Lupo, Mélanie Gillard, Hanane Ouakrim, Navas Victor, Di Bartolo Vincenzo, Pierre Emmanuel Joubert, Oliver Kepp, Guido Kroemer, Marco Alifano, Diane Damotte, and Isabelle Cremer.

ABSTRACT

In non-small cell lung carcinoma (NSCLC), stimulation of toll-like receptor 7 (TLR7), a receptor for single stranded RNA, is linked to tumor progression and resistance to anticancer chemotherapy. However, the mechanism of this effect has been elusive. Here, using a murine model of lung adenocarcinoma, we demonstrate a key role for TLR7, expressed by malignant (rather than by stromal and immune) cells, in the recruitment of myeloid derived suppressor cells (MDSCs), induced after TLR7 stimulation, resulting in accelerated tumor growth and metastasis. In adenocarcinoma patients, high TLR7 expression on malignant cells was associated with poor clinical outcome, as well as with a gene expression signature linked to aggressiveness and metastatic dissemination with high abundance of mRNA encoding intercellular adhesion molecule 1 (ICAM-1), cytokertains 7 and 19 (KRT-7 and 19), syndecan 4 (SDC4), and p53. In addition, lung tumors expressing high levels of TLR7 have a phenotype of epithelial mesenchymal transition with high expression of vimentin and low abundance of E-cadherin. These data reveal a crucial role for cancer cell-intrinsic TLR7 expression in lung adenocarcinoma progression.

Introduction

Tumors constitute a complex microenvironment, which is composed of genetically altered malignant and non-mutated stromal cells, the latter including fibroblasts, vascular and lymphatic vessels, as well as immune cells. Many tumor-infiltrating immune cells including CD4+ and CD8+ T cells, B lymphocytes, or type 1 macrophages (M1) participate in immunosurveillance, meaning that they are commonly associated with good clinical outcome. Other leukocyte subtypes including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs) and type 2 macrophages (M2) have immunosuppressive functions, meaning that their local presence has a negative clinical impact. The composition of tumor infiltrating immune cells strongly influences the tumor microenvironment and the behavior of the tumor in terms of progression, metastasis and treatment resistance.

Toll-like receptors (TLRs), which recognize ligands from pathogens (pathogen-associated molecular patterns, PAMPs) or dying cells (damaged-associated molecular patterns, DAMPs), are involved in the immune response against pathogens, in thus far that they induce the secretion of inflammatory cytokines and chemokines upon their activation. These receptors are largely expressed by immune cells and epithelial cells but also by several types of tumors cells. The role of TLRs in tumor micro-environment is complex. On one hand, TLRs expressed by immune cells can favor immunosurveillance, because their stimulation favors the maturation and activation of innate and adaptive immune effectors. On the other hand, TLRs expressed by cancer cells may receive stimuli that favor tumor progression.

We have previously demonstrated that TLR7, a single stranded RNA receptor that is usually expressed in endosomes of immune cells including plasmacytoid and conventional dendritic cells (pDCs and cDCs), macrophages and B lymphocytes, is expressed by malignant cells from NSCLC patients. High expression by cancer cells was associated with poor prognosis, both in early stages that were treated with surgery alone and more advanced stages treated by neo-adjuvant chemotherapy. Moreover, in a mouse model of lung cancer, TLR7 stimulation favored tumor growth. The present study has been designed to decipher the mechanisms involved in the pro-tumorigenic and possible pro-metastatic effects of TLR7 stimulation.

Keywords

TLR7; lung adenocarcinoma; metastasis; EMT; MDSC

CONTACT Isabelle Cremer isabelle.cremer@crc.jussieu.fr INSERM U1138, Centre de Recherche des Cordeliers, 15 rue de l'Ecole de Medecine, 75006, Paris, France.

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Here, we report that the stimulation of TLR7 expressed by malignant cells favors tumor progression and metastasis, increases CCL2 and GM-CSF secretion in the tumor microenvironment, and elicits the recruitment of MDSCs into the tumor. In vivo depletion of MDSCs abolished the TLR7-dependent pro-tumorigenic and pro-metastatic effect. Finally, we observed in lung adenocarcinoma patients, that high expression of TLR7 by tumor cells is associated to a pro-metastatic gene expression signature as well as to epithelial–mesenchymal transition (EMT).

Results

Intratumoral TLR7 agonist injection favors tumor progression through a direct effect on carcinoma cells

Murine lung adenocarcinoma LLC-luc cells express several TLRs including TLR4, TLR7 and TLR9 (Figure 1A-C). Expression of TLR7 was also validated by quantitative PCR (data not shown). We have previously demonstrated that intratumoral injection of TLR7 agonist results in increased tumor progression in immunocompetent as well as in immune-deficient mice. However, the precise mechanisms involved in such pro-tumorigenic effects are elusive. To determine if this effect was specific, we analyzed the growth of subcutaneous grafted LLC-luc tumors in wild-type (WT) mice locally injected with TLR4, TLR7 or TLR9 agonists. Bacterial lipopolysaccharide (LPS), an agonist of TLR4, failed to affect tumor growth (Figure 1A), while CpG, an agonist of TLR9, actually inhibited tumor growth (Figure 1B). On the contrary, intratumoral injection of the TLR7 agonist CL264 induced a pro-tumorigenic effect (Figure 1C), in accordance to our previous observations.

The pro-tumorigenic effect of TLR7 stimulation could result from a direct stimulation of TLR7 on tumor cells and/or from stimulation of immune cells that express TLR7. We determined the level of TLR7 expression of immune cells in the tumor, the spleen and the blood of tumor-bearing mice by flow cytometry after optimization of the gating strategy (Figure S1). TLR7 was highly expressed by macrophages, pDCs, and to a lesser extent by cDCs in all compartments including the tumor (Figure S2). Thus, TLR7 agonists may act both on malignant cells and on tumor-infiltrating myeloid cells to favor tumor progression.

To discriminate the target population of TLR7 agonist, we took advantage of TLR7-deficient mice (TLR7 KO), and generated TLR7-deficient LLC-luc cells (LLC TLR7 KO) by CRISPR/Cas9-mediated gene editing (Figure 1D). We injected WT (TLR7 expressing) LLC-luc cells into TLR7 KO mice or alternatively TLR7-deficient LLC-luc cells into WT mice, and then evaluated the effects of the TLR7 agonist CL264 on tumor progression. We observed a growth accelerating effect of CL264 in TLR7 KO mice, similar to that observed in WT mice (Figure 1C). In sharp contrast, the TLR7 agonist failed to stimulate the growth of TLR7-deficient LLC-luc tumors (Figure 1D). These results clearly demonstrate that the pro-tumorigenic effect of CL264 effect is mediated by an effect on TLR7 expressed by malignant (rather than immune) cells.

Stimulation of TLR7 alters the intratumoral immune infiltrates

TLR stimulation is known to modify the inflammatory microenvironment of tumors. We analyzed whether the local injection of TLR7 agonist would impact the composition of the immune infiltrate. Immune phenotyping by flow cytometry (for gating strategy see Fig. S1) revealed the percentages of T, B and NK cells, Tregs, macrophages, cDCs, pDCs and MDSCs, including granulocytic and monocytic subpopulations. The immune infiltrate of vehicle-only treated tumors was composed by a majority of myeloid cells including 49% of MDSCs, 15% of cDCs and 5% of macrophages, as well as a by a minority of adaptive immune cells including 10% T cells, 5% NK cells and 3% Tregs (Figure 2A). The local injection of CL264 induced a modification of percentages and absolute cells numbers of MDSCs, with a significant (unpaired Student T test, p < 0.05) increase from 49 ± 7% to 66 ± 10% (Figure 2A-C). CL264 also induced a decrease of cDCs (from 15% ± 1% to 9%± 2%) and of pDCs (from 2% to 1.5%) (Figure 2D-E). In control tumors, MDSCs were mostly monocytic, and CL264 treatment resulted in the increase of granulocytic MDSCs (Figure 2F-G). In contrast, CL264 did not affect the frequency of macrophages, NK, T, Tregs, and B cells (Figure 2A, Fig. S3A).

CL264 stimulates MDSC recruitment by acting on TLR7 expressed by malignant cells

We investigated if the increase of MDSCs within the tumor was a consequence of TLR7 stimulation on cancer or immune cells. The TLR7 agonist CL264 was injected into LLC-luc tumors that were established in WT or TLR7 KO mice.

At baseline levels (without CL264 treatment), WT and TLR7 KO mice showed low frequencies of MDSCs, cDCs and macrophages in their blood and spleens (Fig. S4A, B). TLR7 KO mice exhibited a lower proportion of MDSCs, cDCs, NK and T cells and increased proportion of B cells in the spleen and the blood compared to WT mice (Fig. S4A, B). The tumor immune infiltrate was characterized by high frequencies of MDSCs, both in TLR7 KO and in WT mice. Higher proportions of macrophages and T cells and lower proportions of cDCs were detected in the tumors of TLR7 KO compared to WT mice (Fig. S4C).

In tumors growing on TLR7 KO mice (Figure 2H-N), compared to WT mice (Figure 2A-G) the injection of TLR7 agonist increased the proportion and absolute number of MDSCs (Figure 2H-J), with a marked shift towards a granulocytic MDSC phenotype (Figure 2K), concomitant with a slight decreased proportion of cDCs (Figure 2K), but did not modify the frequency of pDCs (Figure 2L), macrophages, NK, T, Tregs and B cells (Fig. S3B).

Collectively, these data indicate that CL264 maintains its local immunomodulatory function resulting in an increased presence of MDSCs in WT and TLR7 KO mice.

Mdcs are involved in the pro-tumorigenic effect mediated by TLR7 stimulation

To decipher the possible role of MDSCs in the tumor growth stimulatory effect of CL264, we experimentally depleted
MDSCs from the system. Tumor bearing mice that were treated with CL264 or vehicle only received intraperitoneal injections of anti-Gr1 monoclonal antibody (mAb) or control isotype every 48 hours (Figure 3A). During the experiment, less than 0.4% of MDSCs were detectable in the blood of mice, confirming the efficacy of MDSC depletion (Figure 3B-C). MDSC depletion resulted in decreased tumor growth, both in WT and in TLR7 KO mice (Figure 3D, G). The TLR7 agonist CL264 stimulated tumor growth (Figure 3E, H), and this pro-tumorigenic effect was completely lost in the absence of MDSCs, both in WT mice (Figure 3F) and in TLR7 KO mice (Figure 3I).

These results demonstrate that the tumor growth exacerbating effect of TLR7 stimulation is mediated by the increased number of MDSCs within the tumor microenvironment.

**TLR7 stimulation induced an increased production of CCL2 and GM-CSF within the tumor microenvironment**

Given the involvement of MDSCs in the pro-tumorigenic effect of TLR7 stimulation, we investigated the mechanisms that might be involved in the local CL264-induced MDSCs expansion. Several cytokines such as IL-6, GM-CSF or CCL2 stimulate the recruitment or proliferation of MDSCs and may be produced by tumor cells. Local injection of the TLR7 agonist CL264 enhanced the ELISA-detectable concentration of CCL2 and GM-CSF within the tumor. The concentrations of CCL2 and GM-CSF were 10407 ± 1326 and 256 ± 15 pg/ml, respectively, in mice treated with CL264, and 7453 ± 1380 and 186 ± 15 pg/ml, respectively, in control mice receiving PBS (Figure 3J, K). In contrast, CL264 failed to significantly modulate the amount of IL-6 found in the tumor (Figure 3L). The secretion of CCL2 and GM-CSF by tumor cells was confirmed in vitro, which was found increased in supernatants of CL264-stimulated cells (Figure 3M, N).

These results suggest that CL264 may stimulate the recruitment of MDSCs via the induction of CCL2 and GM-CSF.

**TLR7 agonist does not modify the immunosuppressive capacities of mdscs**

To unravel the possible impact of TLR7 stimulation on MDSCs functions, we measured the production of molecules involved in MDSCs-mediated immunosuppressive circuitries. The production of nitrate, H₂O₂, and arginase 1 by MDSCs was not affected by CL264 injection. Similarly, the proportion of ROS producing cells was not altered by CL264 (Fig. S3A). In addition, the capacity of MDSCs to suppress T cell proliferation was similar for MDSCs purified from PBS-treated and CL264-treated tumors (Fig. S5B-C). These results demonstrate that intratumoral injection of TLR7 agonist does not modify the immunosuppressive properties of intratumoral MDSCs.

**MDSC are involved in the pro-metastatic effect of TLR7 stimulation**

Next, we analyzed the capacity of CL264 to stimulate lung metastasis. NOD/SCID or C57BL/6 mice were subcutaneously grafted with LLC-luc cells, and the apparition of metastasis was imaged over time, by bioluminescence or precisely quantified at necropsy following perfusion with Indina Ink and labelling of the lungs with Feket solution. Either of these methods revealed the capacity of CL264 to stimulate lung metastasis, both in immunodeficient NOD/SCID mice (Figure 4A) and in immunocompetent C57Bl/6 mice (Figure 4B).

The number of metastasis was quantified in PBS- and CL264-treated mice. We observed the presence of lung metastases in both groups of mice, but the mice having received three injections of TLR7 agonist had a significantly higher number of metastases with a mean of 9.5 (± 7.5) metastases per lungs for CL264-treated mice, compared to 4.9 (± 4.5) metastases per lungs for the control group (Figure 4C). Repeated injections of CL264 (every three days throughout the duration of the experiment) led to even higher number of lung metastasis (19.5 (± 11.5) metastasis per lungs) (Figure 4D). These results indicate that TLR7 stimulation has a marked pro-metastatic effect.

Given the implication of MDSC in metastatic dissemination, we investigated the potential role of MDSCs in the pro-metastatic effects of TLR7 stimulation. MDSC depletion by injection of anti-Gr1 mAbs led to a significant decrease in the number of metastases (mean of 2.5 (± 2) metastases per lungs) in CL264-treated mice compared to control mice that did not receive depleting antibody (mean of 6.5 (± 4) metastases per lungs) (Figure 4E). These results indicate that TLR7 stimulation increases the number of lung metastases through a mechanism involving MDSCs.

**High expression of TLR7 in human lung adenocarcinoma is associated with a metastatic gene expression signature**

We further characterized the in vitro impact of CL264 on metastatic properties of malignant cells. The stimulation of LLC cells with CL264 resulted in epithelio-mesenchymal transition gene expression signature, with an increased gene expression of N-cadherin, vimentin, snail1, snail 2 and zeb, and a decreased expression of E-cadherin (Figure 5A, B).

Immunohistochemistry was then used to determine the expression of E-cadherin, associated to epithelial cell

---

**Figure 1. Pro- or anti-tumoral effects of different TLRs stimulation.**

Left panel: TLR4 (A), TLR9 (B) and TLR7 (C) expression by LLC-luc cells and TLR7 expression by LLC-luc cells deficient for TLR7 (obtained by CRISPR/Cas9 technology) (D). Control isotype is shown in blue and stained cells in orange. Right panel: Tumor progression in WT C57Bl/6 mice grafted with LLC-luc cells, after LPS (A) or CpG injection (B). Tumor progression in WT C57Bl/6 or in TLR7 KO mice grafted with LLC-luc cells after CL264 injection (C). Tumor progression in WT C57Bl/6 mice grafted with TLR7-deficient LLC-luc cells (LLC TLR7 KO) after CL264 injection (D). Data are mean ± SEM (5 mice/group). *: p < 0.05, **: p < 0.01, ***: p < 0.001. ns = not significant. Each experiment was repeated three times.
phenotype, and that of vimentin, expressed by mesenchymal cells, on human malignant cells expressing high or low levels of TLR7. Forty-five adenocarcinoma patients were analyzed for the expression of TLR7, E-cadherin and vimentin (for representative staining patterns see Figure 6A). Patients were divided into two groups that were expressing TLR7 or not on malignant cells. The expression of E-cadherin and vimentin by tumor cells was determined in a semiquantitative fashion. In TLR7$^{hi}$ patients, the expression of E-cadherin was significantly lower (25.6%±3.7% of cancer cells expressing E-Cadherin) than in TLR7$^{low}$ patients (49.3%±7% of tumor cells expressing E-cadherin) (Figure 6B). Concomitantly, in TLR7$^{hi}$ patients, the expression of vimentin was higher (34.6%±6.7% of tumor cells expressed vimentin), than in TLR7$^{low}$ patients (15.3%±3.6% of tumor cells expressed vimentin) (Figure 6C). In conclusion, in patients with lung adenocarcinoma, high expression of TLR7 on cancer cells is associated with signs of EMT.

Figure 2. TLR7 stimulation alters intratumoral immune infiltrates.

WT (A-G) or TLR7 KO (H-N) C57BL/6 mice received subcutaneous injection of LLC-luc cells, followed by 4 injections of CL264 (red) or PBS (blue), on days 0, 3, 6 and 9. The percentages and absolute numbers of immune cells were analyzed 10 days after. Radar plot representation for immune cell subpopulations is shown in (A) and (H), Representative flow cytometry image of Gr1$^+$CD11b$^+$ MDSC cells in WT (B) and in TLR7 KO mice (I), having received PBS or CL264. Percentages and absolute numbers of each cell population in WT (C-G) and in TLR7 KO mice (J-N). Data are mean ± SEM (5 mice/group). *: p < 0.05, **: p < 0.01, ***: p < 0.0001. ns = not significant. Each experiment was repeated three times.
We then determined the physiopathology impact of TLR7 expression on the metastasis process in a large cohort of adenocarcinoma patients. We first determined the prognostic value of TLR7 on a cohort of 154 adenocarcinoma patients (sup Table 1), the malignant cells of whom displayed TLR7 either at a rather low level (< 5%) or were almost completely positive (> 82%, cut off determined in 11). We found that high TLR7 expression by tumor cells was associated with poor clinical outcome compared to low TLR7 expression, with a median OS of 45 months, compared to 90 months, respectively (Figure 7A). Multivariate analysis revealed TLR7 expression as an independent prognostic marker (Table 1). We then selected twelve patients from this cohort, including six patients having low (< 5%, TLR7low) and six having high (100%, TLR7hi) TLR7 expression, and performed gene expression analysis using nanostring technology and the pan cancer progression panel. Volcano plot analysis revealed that among 770 genes analyzed, six were significantly overexpressed and five were underexpressed in TLR7hi compared to TLR7low patients (Figure 7B). Unsupervised clustering of differentially expressed genes, revealed a small cluster of three genes including ICAM1, keratin 7 (KRT-7) and keratin 19 (KRT-19) that were overexpressed in TLR7hi patients. Additionally, NME1 (encoding nucleoside diphosphate kinase 1) and syndecan 4 (SDC4) (heparin sulfate proteoglycan molecule) were found overexpressed in the TLR7hi group of patients (Figure 7C). More detailed box-plot analysis of these genes confirmed their overexpression in TLR7hi patients (Figure 7D). Interestingly, TP53 was also found highly expressed in TLR7hi patients (Figure 7D). We then searched for correlation between the level of gene expression and survival of adenocarcinoma lung cancer patients, using the public software KM plotter 13. High expression of KRT-7 and KRT-19, as well as that of NME1 and TP53, significantly correlated with poor clinical outcome (Figure 7E).

Collectively, these data indicate the existence of a gene signature that is associated to TLR7 expression by malignant cells as well as with poor prognosis.

Discussion

Our present data indicate that TLR7 stimulation induces pro-tumorigenic and pro-metastatic effects in a preclinical model of lung cancer while providing two salient insights. First, our data indicate that TLR7 must be expressed by the cancer cells (rather than by immune cells) so that the local presence of a TLR7 agonist can stimulate tumor growth. Second, we reveal the direct involvement of MDSCs in both the tumor growth-promoting and pro-metastatic effects of TLR7 stimulation. The presence of excess amount of a TLR7 agonist within the tumor causes an expansion of the number of MDSCs yet fails to enhance their immunosuppressive capacity. Our results also suggest that MDSC recruitment is mediated via a higher CCL2 and GM-CSF production in the tumor microenvironment after TLR7 stimulation. In addition, we demonstrated that high TLR7 expression by tumor cells from adenocarcinoma patients is associated to signs of EMT, as well as to a pro-metastatic gene expression signature. In particular, we observed a higher expression of KRT-7, KRT-19 and TP53, which are associated to the metastasis process and to a poor prognosis.

Previous studies have reported pro-tumorigenic effects for different TLRs, such as TLR3 14–18, TLR4 19–23, TLR5 24, TLR7 10,11,25 and TLR9 26–30. In prostate and breast cancer, the stimulation of TLR9 induced an over-expression of matrix metalloproteinase 13 as well as an increase of cell invasion 31,32. Finally, TLR4 stimulation increased tumor cells invasion in breast cancer 19 and in lung adenocarcinoma 33.

MDSC, a cell type with marked immunosuppressive properties 34, has been linked to tumor progression in various murine models of cancer 35–37. In cancer patients, the number of circulating MDSCs significantly increases compared to healthy subjects 38. Our study, however, is the first demonstration in a cancer model that TLR stimulation leads to local MDSCs expansion, accounting for enhanced tumor growth and metastasis.

TLR7 stimulation has previously mostly reported to stimulate anticancer immunosurveillance, for instance through direct stimulation of TLRs on antigens presenting cells, leading to their maturation 39,40. However, in recent years, TLR7 expression by tumor cells has been associated with a pro-tumoral effect in pancreatic adenocarcinoma 25 and in NSCLC 10,11. We found that stimulation of TLR7 expressed by adenocarcinoma cells modulated the immune infiltrate, leading to a significant expansion in MDSCs, associated with an increased secretion of CCL2 and GM-CSF in the tumor microenvironment. Both these cytokines are known to play a key role in the recruitment of MDSCs 38,41,42. Indeed, the absence of CCL2 production by cancer cells considerably reduces the recruitment of MDSCs into tumors 42.

Importantly, TLR7 stimulation had a pro-metastatic effect, while MDSC depletion drastically reduced this number of metastasis. In melanoma, MDSCs are associated with tumor progression, signs of EMT such as decreased E-Cadherin expression and increased migratory capacities of malignant cells 36. Similarly, MDSCs may contribute to metastatic dissemination of different types of cancer, including NSCLC 43. Finally, Srivastava’s team demonstrated that when MDSCs were depleted, the size of tumors decreased and cell migration was reduced 44.
In line with the involvement of EMT in the metastatic process, we found that TLR7 expression in lung adenocarcinoma was associated with EMT. We observed that a high expression of TLR7 was associated with low expression of E-cadherin and overexpression of vimentin. EMT is a process in which cells lose adhesive properties because of down-regulating E-cadherin expression and rearrange their cytoskeleton through enhanced vimentin expression. These changes in cancer cells play a critical role in metastasis development.

In adenocarcinoma patients, high TLR7 expression was associated with gene expression signature possibly linked to metastasis, with overexpression of KRT-7, KRT-19 and SDC4. These three genes have already been ascribed with pro-metastatic properties in different types of cancers. Indeed, KRT-7 is established as a diagnostic marker in a variety of malignancies including biliary duct, bladder, breast, cervix, kidney, liver, lung adenocarcinoma, ovary and pancreas cancer. In patients with lung adenocarcinoma, strong expression of KRT-7 was associated with a poor overall survival. Keratin 19 is a diagnostic marker in some tumors, such as in biliary duct, bladder, breast, cervix, colon, lung adenocarcinoma, ovary, pancreas, pleura, prostate, stomach and uterus cancer. In addition, KRT-19-positive hepatocellular carcinomas highly express invasion-related/metastasis-related markers. Finally, SDC4 plays a role in the development and metastatic occurrence in renal cell carcinoma.

Strong expression of TLR7 in patients with lung cancer is associated with poor survival prognosis but also with a pro-metastatic gene signature. As a result, it would be interesting to explore the molecular etiology of this pathogenic TLR7 overexpression. Ligation of TLR7 by agonists can stimulate TLR7 expression in a feedforward loop, which implies that high TLR7 abundance might be a sign of the natural stimulation of this receptor by ligands present in the tumor microenvironment. The molecular nature and source of such natural TLR7 agonists remains to be clarified. Moreover, it will be important to develop and characterize TLR7 antagonists or inhibitors of TLR7-elicited signals that might have immunostimulatory and anticancer effects.

**Materials and methods**

**Cell lines**

LLC-Luc cells (gift from Vincenzo di Bartolo, Institut Pasteur, Paris) were obtained from LLC cells (Lewis Lung Carcinoma, ATCC CRL-1642) that were stably transfected with firefly luciferase. LLC-Luc cells were cultured in DMEM+ GlutaMax (Gibco) with 10% heat-inactivated FCS, 1% penicillin/streptomycin mixture, and 0.5mg/ml hygromycin B. The cumulative culture length of the cells was fewer than 6 months after resuscitation. Early passage cells were used for all experiments and they were not reauthenticated.

**Mice**

Wild-type C57Bl/6j mice, mice deficient in TLR7 (B6.129S1-Tlr7tm1Flv/f strain), and NOD/SCID mice were purchased from Charles River Laboratories. All the animals were house kept at CEF (Centre d’Explorations Fonctionnelles de Centre de Recherche des Cordeliers, Agreement no. A75-06-12). They were maintained in a constant temperature and humidity in light controlled room with a 12 hours light cycle. They had free access...
to food (SAFE Laboratory) and tap water. All experiments were conducted in 6–8 week-old female mice in accordance with the institutional guidelines and the recommendations for the care and use of laboratory animals put forward by the Directive 2010/63/EU revising Directive 86/609/EEC on the protection of animals used for scientific purposes (project has been approved by a user establishment’s ethics committee and the Project Authorization: number Ce5/2010/057 and 6629).

### Tumor growth and metastasis

Cancer cells ($1 \times 10^6$ in 100µl PBS/injection) were injected into the flank of recipient mice. Mice then received intra-tumor injections of LPS (40 µg/injection), CL264 (40 µg/injection) or CpG (30 µg/injection) (Invivogen) at day 0, 3 and 6 after tumor grafting. Tumor volume (length (l), breath (b), depth (d)) was measured every 2–3 days using caliper, and was calculated taking into account the three values according to the ellipsoid volume calculation formula: tumor volume = $\frac{4}{3} \pi \times \frac{l}{2} \times \frac{b}{2} = 0.5236 \times l \times b \times d$. For metastasis detection, mice were injected (i.p.) with body weight D-luciférrine K+ (Interchim), then were anaesthetized using isoflurane, 10 minutes before imaging for bioluminescence using an IVIS imaging system (Lumina II). Mice were sacrificed between days 22 and 24. The rib cage was excised and 1 ml of India ink (7.5% solution) was injected into the trachea. The lungs were harvested and washed with 1X PBS. Separation of lobes and connectives tissues elimination was performed. The lungs were immersed and stored in 1ml of Feket solution (300ml of 70% ethanol, 30ml of 37% formaldehyde and 5 ml of glacial acetic acid). The number of metastatic foci was counted.

### Mdscs depletion

When tumors were palpable, mice were injected (i.p.) with anti-Gr1 (clone RB6-8C5, BioXCell) or control antibody (clone LTF-2, BioXCell) (200µg/injection, in 100µl PBS) every 48 hours. MDSC depletion was confirmed in the peripheral blood of recipient mice. Blood sample was recovered in heparin containing tubes. After red blood cell lysis by ACK, nucleated cells were incubated for 20 minutes at 4°C with

---

**Figure 5.** TLR7 stimulation of LLC cells leads to epithelio-mesenchymal signature.

Gene expression of membrane molecules (A) and transcription factors (B) involved in epithelio-mesenchymal transition, in LLC cells that were stimulated or not with CL264, determined 12 and 24h after stimulation.

![Figure 5](image-url)
blocking antibody (24G2, 1mg/ml, 1/100). Cells were stained for 30 minutes at 4°C with the following antibodies: PECy7 anti-CD45 (Clone 30-F11, BD Pharmingen, 1/800), eF450 anti-CD11b (Clone M1/70, eBioscience, 1/100), PerCPCy5.5 anti-Gr1 (Clone RB6-8C5, BD Pharmingen, 1/100), PE anti-CD11c (Clone N418, eBioscience, 1/100) and LIVE/DEAD® Fixable Yellow Dead Cell Stain Kit (Life Technologies, L34959, 1/100). Staining was assessed with a FACS Fortessa cytometer, and flow cytometry data were analyzed using FACSDiva (BD Biosciences) or FlowJO (Tree Star) software.

**Preparation of single cell suspensions and flow cytometry analyzes**

Mice were sacrificed 10 days after cancer cell injection, and tumors and spleens were excised, mechanically dissociated, and incubated at 37°C for 30 minutes with DNase I (1mg/ml, Roche) and liberase TM (2.5mg/ml, Roche). Resulting single-cell suspensions were filtered through 70µm cell strainers (BD), and were incubated for 20 minutes with blocking antibody (24G2, 1mg/ml, 1/100). Cells were then stained for 30 minutes with LIVE/DEAD® Fixable Yellow Dead Cell Stain Kit (Life Technologies, L34959) and the following antibodies: PECy7 anti-CD45 (clone 30-F11, BD Pharmingen, 1/800), APC-eF780 anti-CD3 (clone UCHT1, eBioscience, 1/100), PETR anti-CD4 (clone GK1.5, Caltag, 1/100), AF700 anti-CD8 (clone 53–6.7, eBioscience1/100), PE anti-CD19 (clone 1D3, BD Pharmingen, 1/100), BV605 anti-NK1.1 (clone PK136, Biolegend, 1/50), FITC anti-CD11b (clone M1/70, BD Pharmingen, 1/100), eF450 anti-CD11b (clone M1/70, eBioscience, 1/100), BV786 anti-CD11c (clone HL3, BD Pharmingen, 1/50), BV605 anti-Gr1 (clone RB6-5C8, BD Pharmingen, 1/100), AF700 anti-F4/80 (clone CI:A3-1, AbD serotec). For the FoxP3 and TLR7 labeling, the cells were first incubated with fixation/permeabilisation reagent (eBiosciences),
as recommended by the manufacturer and then stained during 30 minutes with AF647 anti-FoxP3 antibody (Biolegend) or PE anti-TLR7 antibody (BD Pharmingen).

Staining was assessed with a FACS Fortessa cytometer, and flow cytometry data were analyzed using FACSDiva or FlowJO software.
Cytokine detection by ELISA

Mice were sacrificed 10 days after cancer cell injection and tumors were excised, cut into pieces of 1 mm³ and placed in RPMI medium supplemented with 1% penicillin/streptomycin and 1% Glutamine for 24h at 37°C. Supernatants were then collected and stored at −80°C.

100000 LL/2 cells were cultured in a 12 well plate for 12 or 24 hours along with TLR7 agonist (2.5 µg/mL CL264), supernatants were collected and stored at −80°C.

Cytokine production was quantified by using GM-CSF ELISA ready-SET-Go! (88–7334-22), mouse CCL2 (MCP-1) ELISA ready-SET-Go! (88–7391-22) and mouse IL-6 ELISA ready-SET-Go! (88–7064-22) from eBiosciences, using the protocols provided by the manufacturer.

Mdscs sorting and biological activity

Mice were sacrificed 10 days after cancer cell injection and tumors were excised. Single cell suspension was prepared and incubated in blocking solution (24G2, 1mg/ml, 1/100), during 20 minutes, then stained for 30 minutes at 4°C with PECy7 anti-CD45, eF450 anti-CD11b, PerPCy5.5 anti-Gr1, and LIVE/DEAD+ Fixable Yellow Dead Cell Stain Kit. After cell sorting using a FACS Aria cytometer, sorted cells were centrifuged and cultured overnight in RPMI medium with 10% FBS. Labeled cells were then incubated for 72 h, in the presence or not or sorted Gr1+ CD11b+ cells. T cell proliferation was determined by flow cytometry.

Patients

A retrospective series of 154 lung adenocarcinoma stage I-III patients who underwent primary surgery (without neoadjuvant chemotherapy) and who were operated between 2001 and 2005 was obtained from Hotel-Dieu hospital (Paris, France). Lung tumor samples were analyzed with the agreement of the French ethic committee (agreements 2008–133 and 201206–12) in accordance with article L.1121–1 of French law.

Immunohistochemistry

Human tumor samples were fixed in neutral-buffered 10% formalin solution and paraffin embedded. TLR7 staining and quantification was performed as previously described 11 using TLR7-specific polyclonal antibody (ENZO Lifesciences) at 10 mg/mL.

The expression of E-cadherin (Dako M3613, 1/100 dilution) and vimentin (Cells Signaling 5741, 1/100) by tumor cells was performed as follows. Serial 5-µm tissue sections were deparaffinized, rehydrated, and pretreated in 10 mM citrate buffer, pH 6, for antigen retrieval. Sections were incubated with hydrogen peroxide for 15 minutes, then blocked in 5% human serum for 30 minutes at room temperature. The slides were then incubated with a primary antibody (diluted in Dako real solution, antibody diluent) anti-E-cadherin (Dako M3613, 1/100 dilution) or anti-vimentin (Dako M3613, 1/100 dilution) for one hour at room temperature or anti-vimentin (Cells Signaling 5741, 1/100) overnight. Slides were then incubated for 30 minutes at room temperature with the secondary antibody (anti-rabbit coupled to biotin, 1/200, JIR 715–066-150), followed by 30 minutes incubation with

---

Table 1. Univariate and multivariate analysis for 154 patients with lung adenocarcinoma not treated with neoadjuvant chemotherapy.

| Variable                      | Univariate analysis | P     | HR (95% CI)     |
|-------------------------------|---------------------|-------|-----------------|
| TLR7 (> 82% vs < 5%)          | 0.027               | 1.56  | (1.1 – 2.3)     |
| TLR7 (medium vs < 5%)         | 0.49                | 1.15  | (0.78 – 1.7)    |
| Gender (male vs female)       | 0.17                | 1.19  | (0.93 – 1.5)    |
| Smoking status (smoker vs non smoker) | 0.72            | 1.05  | (0.79 – 1.4)    |
| Pathologic stage              |                     |       |                 |
| IB vs IA                      | 0.11                | 1.37  | (0.93 – 2)      |
| IIA vs IA                     | 0.42                | 1.22  | (0.76 – 2)      |
| IIB vs IA                     | 0.0078              | 1.81  | (1.2 – 2.8)     |
| IIIA vs IA                    | <0.0001             | 2.86  | (2 – 4.1)       |
| IIIIB vs IA                   | 0.00012             | 3.42  | (1.8 – 6.4)     |
| IV vs IA                      | 0.0045              | 2.74  | (1.4 – 5.5)     |
| Multivariate analysis         |                     |       |                 |
| TLR7 (> 82% vs < 5%)          | 0.02                | 1.62  | (1.1 – 2.4)     |
| TLR7 (medium vs < 5%)         | 0.6                 | 1.11  | (0.74 – 1.7)    |
| Pathologic stage              |                     |       |                 |
| IB vs IA                      | 0.42                | 1.21  | (0.75 – 2)      |
| IIA vs IA                     | 0.5                 | 1.21  | (0.69 – 2.1)    |
| IIB vs IA                     | 0.022               | 1.93  | (1.1 – 3.4)     |
| IIIA vs IA                    | <0.0001             | 2.60  | (1.6 – 4.1)     |
| IIIIB vs IA                   | 0.011               | 1.99  | (1.4 – 12)      |
| IV vs IA                      | 0.062               | 6.92  | (0.91 – 53)     |
streptavidin-HRP (Dako, 1/300). After each incubation, the slides were washed 5 minutes with 1x TBS+ 0.04% Tween. Revelation was performed with the DAB kit (Dako, K3468) and stopped by placing slides in 1X TBS and distilled water. Counter coloration was performed with hematoxylin.

**Gene expression analysis**

RNA extraction was performed on LCC-Luc cells stimulated or not with 2.5 µg/mL CL264 using the Maxwell®16 LEV simplyRNA cells kit manufacturer procedure. 200 µg of RNA were used for RT-PCR with High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor kit from (Applied Biosystems) and the pPCR was performed using Taqman probes (FAM- Applied Biosystems: E-Cadherin (Mm01247357_m1), N-Cadherin (Mm01162497_m1), Keratin 19 (Mm00492980_m1), Keratin 7 (Mm00466676_m1), Vimentin (Mm01333430_m1), NME 1 (Mm01612215_m1), snail 1 (Mm00441533_g1), snail 2 (Mm00441531_m1), twist1 (Mm00442036_m1) and the housekeeping gene, GAPDH (Mm99999915_g1).

Twenty µm of FFPE sections were obtained from paraffin blocks. Deparaffination was performed by adding 1 mL 100% clearene for 5 min at room temperature. After centrifugation the pellet was washed twice with 1 mL 100% ethanol. Protease digestion was performed by adding digestion buffer and protease form RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (AM1975), then samples were incubated 3h at 50°C and for 15 min at 80°C for RNA isolation. Gene expression analysis was performed on 100ng RNA, using nCounter XT gene expression assays from nanosting (pancancer progression panel), following the recommendations of the manufacturer.

**CRISPR/CAS9 mediated tlr7 gene editing**

LLC-luc cells were transiently transfected with a plasmid coding for Tlr7-targeting gRNA and Cas9 protein fused to a red fluorescent protein (RFP) (Sigma Aldrich, St. Louis, MO, US) by means of lipofectamin 2000 (Thermo Fisher scientific, Waltham, MA, US) according to the manufacturer recommendation. The following day, RFP expressing cells were selected by single cell sort using a BD FACS Aria Fusion (Becton Dickinson, Franklin Lakes, NJ, US). Following TLR7-deficient clones were then selected.

**Statistical analysis**

Statistical analysis for in vivo experiments was performed using GraphPad Prism 5 (GraphPad Software) and the R software (RFoundation for Statistical Computing: www.r-project.org) and the package survival. Significance threshold for p values was set to 0.05. All mice experiments were analyzed using two-way ANOVA method. Post hoc analyses with Bonferroni corrections were applied for pair-wise comparisons of tumor growth over time in different groups of mice. Tumor volumes at the endpoint of each experiment were compared using a nonparametric Mann–Whitney test with Bonferroni corrections for pair-wise comparisons. Mann–Whitney tests were also used to compare percentages and numbers of immune cells infiltrating the tumors in mice. Overall survival (OS) curves were estimated by the Kaplan – Meier method and compared by the log-rank test. The OS was defined from the date of the surgery until the date of death or the last day of the patient’s visit to the hospital. Unsupervised hierarchical clustering was performed with Euclidian distance and Ward linkage criterion. Comparisons of the expression of vimentin and E-cadherin in TLR7 hi and TLR7 low patients were performed using a Mann–Whitney test.

**Abbreviations**

- DAMP: damaged-associated molecular pattern
- EMT: epithelial–mesenchymal transition
- ICAM-1: intercellular adhesion molecule 1
- KRT: keratin
- NSCLC: non-small cell lung cancer
- MDSC: myeloid derived suppressor cells
- PAMP: pathogen-associated molecular patterns
- ssRNA: single-stranded RNA
- SDC4: syndecan 4
- TLR7: toll-like receptor 7
- DDC: diacylglycerol O-acetyltransferase

**Funding**

This work was supported by the “Institut National de la Santé et de la Recherche Médicale” (INSERM), Sorbonne Universite, Universite Paris Descartes, the Cancer Research for Personalized Medicine (CARPEM), the LabEx Immuno-Oncology, and the Institut National du Cancer (2016-1-PLBIO-09-INSERM 6-1).

**Technical support**

We are most grateful for excellent technical assistance of the Centre d’Explorations Fonctionnelles (CEF) crew for their support with the mice. Cell sorting was performed at CICC (Centre d’Imagerie Cellulaire et de Cytometrie, Centre de Recherche des Cordeliers UMR S 1138, Paris, France). CICC is a member of the UPMC Cell Imaging & Flow Cytometry (LUMIC) network and the UPD cell imaging network.

**Notes on contributions**

MD, KI, SM, MG and HO performed experiments; FP performed statistical analysis; VN and VDB provided LLC-luciferase expressing cells; OK and GK performed CRISPR/cas9 TLR7 deletion on LLC-luc cells; AL and DD were responsible for clinical data; DD and MA were responsible for pathological data; IC, MD, KI and PEJ interpreted the data; IC designed and supervised the study; MD, KI, GK and IC wrote the manuscript.

**ORCID**

Kristina Iribarren [http://orcid.org/0000-0002-2930-8573]
Solenne Marmier [http://orcid.org/0000-0002-6671-0940]
Di Bartolo Vincenzo [http://orcid.org/0000-0002-5453-947X]
Oliver Kepp [http://orcid.org/0000-0002-6081-9558]
Guido Kroemer [http://orcid.org/0000-0002-9334-4405]
Isabelle Cremer [http://orcid.org/0000-0002-0963-1031]

**References**

1. Fridman WH, Pagès F, C S-F, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12(4): 298–306. doi: 10.1038/nrc3245.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–674. doi: 10.1016/j.cell.2011.02.013.
5. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012; 4(3): doi: 10.1101/cshperspect.a006049.

6. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006–2010). Expert Opin Ther Pat. 2011; 21(6): 927–944. doi: 10.1517/15403767.2011.569494.

7. Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. Immunobiology. 2017; 222(1): 89–100. doi: 10.1016/j.imbio.2016.06.009.

8. Dajon M, Iribarren K, Cremer I. Dual roles of TLR7 in the lung cancer microenvironment. Oncoimmunology. 2015; 4(3): e991615. doi: 10.4161/2162402X.2014.991615.

9. Dranoff G. Coordinated tumor immunity. J Clin Invest. 2003; 111(8): 1116–1118. doi: 10.1172/JCI118359.

10. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Unkeless J, Li D, Yuan Y, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Biochem Biophys Res Commun. 2006; 331(2): 892–897. doi: 10.1016/j.bbrc.2006.02.018.

11. Rarr TA, Brown S, Ryan G, Zhao J, Gray D. Toll-like receptors. Leukemia. 2006; 20(4): 640–646. doi: 10.1038/sj.leu.2404226.

12. Kitamura T, Qian B-Z, Pollard JW. Immune cell promotion of epithelia and oncogenesis. Nat Cell Biol. 2003; 5(3): E1505174-14.

13. Győrffy B, Surowiak P, Budczies J, Lángczyk A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8(12): e82241. doi: 10.1371/journal.pone.0082241.

14. Farnebo L, Shahangan A, Lee Y, Shin JH, Scheeren FA, Sunwoo JB. Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma. Oncotarget. 2015; 6(12): 9897–9907. doi: 10.18632/oncotarget.6112.

15. Huang B, Zhao J, Shen S, Li H, He K-L, Shen S-H, Mayer L, Unkeless J, Chiong X. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005; 65(12): 5009–5014. doi: 10.1158/0008-5472.CAN-05-0784.

16. Fukata M, Chen A, Klepper A, Krishnareddy S, Vadavena AS, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ, et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology. 2006; 131(3): 862–877. doi: 10.1053/j.gastro.2006.06.017.

17. Dapito DH, Mencin A, Gwak G-Y, Pradere J-P, Jang M-K, Mederacke I, Cavigilia MJ, Khiaibian H, Adeyemi A, Bataller R, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012; 21(4): 504–516. doi: 10.1016/j.ccr.2012.02.007.

18. Rutkowski MR, Stephen TL, Svoronas N, Allegrezza MJ, Tesone AJ, Perales-Puchalt A, Bencicova E, Escovar-Fadul X, Nguyen JM, Cadungen MG, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell. 2015; 27(1): 27–40. doi: 10.1016/j.ccell.2014.11.009.

19. Ochi A, Grafeos CS, Zamirinis CP, Rehman A, Hackman M, Fallon N, Barilla RM, Henning JR, Jamal M, Rao R, et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 2012; 122(11): 4118–4129. doi: 10.1172/JCI63606.

20. Jego G, Bataille R, Geoffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006; 20(6): 1130–1137. doi: 10.1038/sj.leu.2404226.

21. Moreira D, Zhang Q, Hossain DMS, Nechaev S, Li H, Kowolik CM, D’Apuzzo M, Forman S, Jones J, Pal SK, et al. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget. 2015; 6(19): 17302–17313. doi: 10.18632/oncotarget.4029.

22. Zamirinis CP, Levie E, Nguy S, Avanzini A, Barilla R, Xu Y, Seifert L, Daley D, Greco SH, Deutsch M, et al. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J Exp Med. 2015; 212(12): 2077–2094. doi: 10.1084/jem.20142162.

23. Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Simon JM, Cadungog MG, et al. Microbiota drives TLR5-dependent signaling in cancer. Cancer Res. 2015; 75(24): 6534–6543. doi: 10.1158/0008-5472.CAN-15-0318.

24. Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, Lotze M, Tang D, Tsung A. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol. 2015; 63(1): 114–121. doi: 10.1016/j.jhep.2015.02.009.

25. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS. Toll-like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate. 2007; 67(7): 774–781. doi: 10.1002/pros.20562.

26. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS. Toll-like receptor-9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006; 4(7): 437–447. doi: 10.1158/1535-7786.MCR-06-0007.

27. Chow SC, Gowing SD, Cools-Lartigue J, Chen CB, Berube J, Yoon H-W, Chan CHF, Rousseau MC, Bourdeau F, Giannias B, et al. Lactam negative beta-lactam increase non-small cell lung cancer metastasis via Toll-like receptor 4 activation and mitogen-activated protein kinase phosphorylation. Int J Cancer J Int Cancer. 2015; 136(6): 1341–1350. doi: 10.1002/ijc.29111.
34. Gabriolovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12(4): 253–268. doi: 10.1038/nri3175.

35. Liu J, Wang H, Yu Q, Zheng S, Jiang Y, Liu Y, Yuan G, Qiu L. aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in non-small cell lung carcinoma patients. Hum Immunol. 2016; 77(1): 84–89. doi: 10.1016/j.humimm.2015.10.015.

36. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong W-C, Kato M, Prevost-Blondel A, Thiery J-P, Abastado J-P. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011; 9(9): e1001162. doi: 10.1371/journal.pbio.1001162.

37. Feng P-H, Lee K-Y, Chang Y-L, Chan Y-F, Kuo L-W, Lin T-Y, Chung F-T, Kuo C-S, Yu C-T, Lin S-M, et al. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med. 2012; 186(10): 1025–1036. doi: 10.1164/rcrm.2012-0636OC.

38. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25(18): 2546–2553. doi: 10.1200/JCO.2006.08.5829.

39. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 2013; 73(15): 4629–4640. doi: 10.1158/0008-5472.CAN-12-3058.

40. Aspord C, Tramcourt L, Leloup C, Molens J-P, Leccia M-T, Charles J, Plumas J. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization. J Invest Dermatol. 2014; 134(10): 2551–2561. doi: 10.1038/jid.2014.194.

41. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004; 64(17): 6337–6343. doi: 10.1158/0008-5472.CAN-04-0757.

42. Chun E, Lavoie S, Michaud M, Gallini CA, Kim J, Soucy G, Odze R, Glickman JN, Garrett WS. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 2015; 12(2): 244–257. doi: 10.1016/j.celrep.2015.06.024.

43. Huang A, Zhang B, Wang B, Zhang F, Fan K-X, Guo Y-J. Increased CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 2013; 62(9): 1439–1451. doi: 10.1007/s00262-013-1450-6.

44. Mk S, Zhu L, Harris-White M, Uk K, Kar U, Huang M, Mf J, JM L, Elashoff D, Strieter R, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PloS One. 2012; 7(7): e40677. doi: 10.1371/journal.pone.0040677.

45. Thiery JP, Acloque H, Huang RJY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5): 871–890. doi: 10.1016/j.cell.2009.11.007.

46. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011; 30(2): 127–138. doi: 10.1038/onc.2010.456.

47. Pavl M, Olsen KE, Holst R, Donnem T, Busund L-T, Bremnes RM, Al-Saad S, Andersen S, Richardsen E, Ditzel HJ, et al. Keratin 3betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer. Acta Oncol Stockh Swed. 2016; 55(2): 167–177. doi: 10.3109/0284186X.2015.1049291.

48. Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, Ogiso S, Kita S, Yasuda K, Fukushima K, Mizumoto M, et al. Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma. J Cancer Res Clin Oncol. 2012; 138(5): 871–890. doi: 10.1007/s00262-013-1450-6.

49. Erdem M, Erdem S, Sanli O, Sak H, Kilicaslan I, Sahin F, Telci D. Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma. Urol Oncol. 2014; 32(1): 25.e13–20. doi: 10.1016/j.uroonc.2012.08.022.

50. Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes Immun. 2001; 2(6): 349–355. doi: 10.1038/sj.gene.6363791.